(NASDAQ: TNGX) Tango Therapeutics's forecast annual revenue growth rate of -1.86% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.36%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Tango Therapeutics's revenue in 2024 is $37,232,000.On average, 5 Wall Street analysts forecast TNGX's revenue for 2024 to be $3,101,533,293, with the lowest TNGX revenue forecast at $2,243,771,502, and the highest TNGX revenue forecast at $4,508,912,256. On average, 5 Wall Street analysts forecast TNGX's revenue for 2025 to be $3,532,337,422, with the lowest TNGX revenue forecast at $2,671,156,550, and the highest TNGX revenue forecast at $6,165,029,317.
In 2026, TNGX is forecast to generate $3,709,381,678 in revenue, with the lowest revenue forecast at $2,464,943,264 and the highest revenue forecast at $7,030,484,040.